Novo Nordisk Stock Sinks on Weak Sales Forecast

Core Viewpoint - Novo Nordisk A/S is experiencing significant stock declines due to a weak sales forecast despite beating fourth-quarter earnings and revenue estimates, with the company citing "unprecedented" price pressures from competition in the weight-loss drug market and potential drug cost cuts by President Trump [1] Group 1: Stock Performance - Novo Nordisk's stock is down 3.7% to $48.44, extending a previous 14.6% decline, and is now at its lowest levels since December [1][2] - The stock has decreased by 41.4% year over year [2] Group 2: Market Activity - Options trading shows increased bullish sentiment, with 56,000 calls exchanged today, which is double the typical volume, compared to 27,000 puts [2] - The March 45 put is noted as the most active contract [2] Group 3: Options Trading Trends - Over the past 10 weeks, calls have been more popular than usual, with a 50-day call/put volume ratio of 4.59, ranking higher than 97% of readings from the past year [3] - Novo Nordisk stock has historically outperformed options traders' volatility expectations, reflected in a Schaeffer's Volatility Scorecard (SVS) of 89 out of 100 [3]